SCHEMBL26820144

SCHEMBL26820144

O=S(=O)(Nc1ccc2cc[nH]c2n1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 3/20 0.53
HSD17B10 Q99714 2/20 0.53
HPGD P15428 1/20 0.53
GAA P10253 1/20 0.49
PIK3CA P42336 2/20 0.48
POLB P06746 1/20 0.48
PIK3CD O00329 1/20 0.47
PIK3R1 P27986 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
HSD11B1 P28845 1/20 0.44
IL1RN P18510 1/20 0.44
KEAP1 Q14145 1/20 0.44
ERAP1 Q9NZ08 1/20 0.44
EGFR P00533 1/20 0.44
AURKB Q96GD4 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27493659 0.76 KDM4E (0.77) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL12128989 0.73 APP (0.56) PIK3CAPIK3CDPIK3CBPIK3CGAURKB
SCHEMBL19329562 0.73 ALDH1A1 (0.47) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL20575653 0.72 KDM4E (0.60) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL1962405 0.72 PIK3CA (0.75) ALDH1A1KDM4EPIK3CAPIK3CDPIK3R1
SCHEMBL721045 0.71 APP (0.55) ALDH1A1KDM4EHSD17B10GAAMAPK1
SCHEMBL5820194 0.71 ESR1 (0.74) ALDH1A1HPGDGAAPIK3CAIL1RN
SCHEMBL1093985 0.70 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL13485892 0.70 SLC40A1 (0.56) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL19617819 0.69 KDM4E (0.66) ALDH1A1KDM4EHSD17B10HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ALDH1A1 3575/4885KDM4E 4284/4885HSD17B10 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.